Qatar bans unlicensed peptide products

The Ministry of Public Health in Qatar has banned the import, manufacturing, preparation, sale, prescription, dispensing, injection, use, advertising, and promotion of unlicensed peptide products. This includes peptides such as BPC-157, retatrutide, and MOTS-c, which are being marketed for therapeutic, cosmetic, or performance enhancement purposes without proper regulatory authorization. The products are not approved for medical use in humans in Qatar, and many are still in the research, clinical study, or approval stages.

The ministry observed a rise in the promotion, handling, and distribution of these unlicensed peptides, noting that their safety and efficacy have not been adequately established. They pose potential health risks and could jeopardize patient safety. The prohibition also extends to products labeled as "for research purposes" or "not for human use" if they are intended, used, or promoted for human consumption. This ban applies to all promotional activities through social media and other electronic platforms.

The Pharmacy and Drug Control Department pledged to enforce all necessary control, regulatory, and legal measures against violators. They urged healthcare facilities, practitioners, businesses, and individuals to comply fully with the issued circular. Any reports concerning unregulated pharmaceutical products and related inquiries can be submitted by calling 16000 or emailing qhcc@moph.gov.qa.